Claims
- 1. An isolated polynucleotide comprising a heparanese sequence having X contiguous nucleotides, wherein (i) the X contiguous nucleotides have at least about 80% identity to Y contiguous nucleotides derived from SEQ ID NO:2, (ii) X equals Y, and (iii) X is greater than or equal to 50.
- 2. The isolated polynucleotide of claim 1, wherein X is between about 50 and 650, including all integer values between 50 and 650.
- 3. The isolated polynucleotide of claim 1, wherein X is greater than or equal to 650.
- 4. An isolated polynucleotide comprising SEQ ID NO:2.
- 5. An isolated polynucleotide comprising a heparanese sequence having X contiguous nucleotides, wherein (i) the X contiguous nucleotides have at least about 80% identity to Y contiguous nucleotides derived from SEQ ID NO:3, (ii) X equals Y, and (iii) X is greater than or equal to 50.
- 6. The isolated polynucleotide of claim 5, wherein X is between about 50 and 650, including all integer values between 50 and 650.
- 7. The isolated polynucleotide of claim 1, wherein X is greater than or equal to 650.
- 8. An isolated polynucleotide comprising SEQ ID NO:3.
- 9. An expression vector comprising the isolated polynucleotide according to claim 1.
- 10. An expression vector comprising the isolated polynucleotide according to claim 5.
- 11. A host cell comprising the isolated polynucleotide according to claim 1.
- 12. A host cell comprising the isolated polynucleotide according to claim 5.
- 13. A fusion polypeptide comprising
(a) a DNA binding domain targeted to a region of the isolated polynucleotide of claim 1 or claim 5; and (b) a transcriptional regulatory domain or functional fragment thereof.
- 14. The fusion polypeptide of claim 13, wherein the DNA binding domain is a zinc finger DNA binding domain.
- 15. The fusion polypeptide of claim 14, wherein the targeted region is at least 9 nucleotides in length.
- 16. The fusion polypeptide of claim 13, wherein the transcriptional regulatory domain comprises a repression domain.
- 17. The fusion polypeptide of claim 16, wherein the repression domain is selected from the group consisting of (a) KRAB; (b) MBD2B;
(c) v-erbA and (d) functional fragments of (a), (b) or (c).
- 18. The fusion polypeptide of claim 13, wherein the transcriptional regulatory domain comprises an activation domain.
- 19. The fusion polypeptide of claim 18, wherein the activation domain is selected from the group consisting of (a) VP 16; (b) p65 and (c) functional fragments of (a) or (b).
- 20. A polynucleotide encoding the fusion polypeptide of claim 13.
- 21. A cell comprising the polynucleotide of claim 20.
- 22. A cell comprising the fusion polypeptide of claim 13.
- 23. A method of modulating expression of a heparanase gene, the method comprising the step of contacting a region of SEQ ID NO:2 or SEQ ID NO:3 with a molecule that binds to a binding site in the region.
- 24. The method of claim 23, wherein the molecule is a fusion molecule comprising a DNA binding domain and a transcriptional regulatory domain or functional fragments thereof.
- 25. The method of claim 23, wherein the molecule is an endogenous transcriptional regulatory factor.
- 26. The method of claim 23, wherein the region is in the isolated polynucleotide of claim 1.
- 27. The method of claim 23, wherein the region is in the isolated polynucleotide of claim 5.
- 28. The method of claim 23, wherein the region is at least 9 nucleotides in length.
- 29. The method of claim 23, wherein the modulation of the heparanase gene comprises repression of heparanase.
- 30. The method of claim 29, wherein the transcriptional regulatory domain comprises a repression domain.
- 31. The method of claim 30, wherein the repression domain is selected from the group consisting of (a) KRAB; (b) MBD2B; (c) v-erbA and (d) functional fragments of (a), (b) or (c).
- 32. The method of claim 23, wherein the modulation of the heparanase gene comprises activation of heparanase.
- 33. The method of claim 32, wherein the transcriptional regulatory domain comprises an activation domain.
- 34. The method of claim 33, wherein the activation domain is selected from the group consisting of (a) VP16; (b) p65; and (c) functional fragments of (a) or (b).
- 35. The method of claim 23, wherein the heparanase gene is in a plant cell.
- 36. The method of claim 23, wherein the heparanase gene is in an animal cell.
- 37. The method of claim 36, wherein the animal cell is a human cell.
- 38. A recombinant expression construct effective in directing the transcription of a selected coding sequence, said expression construct comprising:
(a) a coding sequence; and (b) control elements that are operably linked to said coding sequence, wherein said control elements comprise a polynucleotide derived from a polynucleotide according to claim 1 or claim 5 or a functional fragment thereof, and wherein said coding sequence can be transcribed and translated in a host cell.
- 39. A host cell transformed with the recombinant expression construct of claim 38.
- 40. A method of modulating expression of a target coding sequence in a host cell comprising the step of contacting the host cell with an expression construct according to claim 38, wherein the expression construct comprises the target coding sequence.
- 41. An isolated polynucleotide comprising a heparanese sequence having X contiguous nucleotides, wherein (i) the X contiguous nucleotides have at least about 80% identity to Y contiguous nucleotides derived from SEQ ID NO:18, (ii) X equals Y, and (iii) X is greater than or equal to 50.
- 42. The isolated polynucleotide of claim 41, wherein X is between about 50 and 650, including all integer values between 50 and 650.
- 43. The isolated polynucleotide of claim 41, wherein X is greater than or equal to 650.
- 44. An isolated polynucleotide comprising SEQ ID NO: 18.
- 45. An expression vector comprising the isolated polynucleotide according to claim 41.
- 46. A host cell comprising the isolated polynucleotide according to claim 41.
- 47. A fusion polypeptide comprising
(c) a DNA binding domain targeted to a region of the isolated polynucleotide of claim 41; and (d) a transcriptional regulatory domain or functional fragment thereof.
- 48. The fusion polypeptide of claim 47, wherein the DNA binding domain is a zinc finger DNA binding domain.
- 49. The fusion polypeptide of claim 48, wherein the targeted region is at least 9 nucleotides in length.
- 50. The fusion polypeptide of claim 47, wherein the transcriptional regulatory domain comprises a repression domain.
- 51. The fusion polypeptide of claim 50, wherein the repression domain is selected from the group consisting of (a) KRAB; (b) MBD2B; (c) v-erbA and (d) functional fragments of (a), (b) or (c).
- 52. The fusion polypeptide of claim 47, wherein the transcriptional regulatory domain comprises an activation domain.
- 53. The fusion polypeptide of claim 52, wherein the activation domain is selected from the group consisting of (a) VP 16; (b) p65 and (c) functional fragments of (a) or (b).
- 54. A polynucleotide encoding the fusion polypeptide of claim 47.
- 55. A cell comprising the polynucleotide of claim 54.
- 56. A cell comprising the fusion polypeptide of claim 47.
- 57. A method of modulating expression of a heparanase gene, the method comprising the step of contacting a region of SEQ ID NO: 18, or a functional fragment thereof, with a molecule that binds to a binding site in the region.
- 58. The method of claim 57, wherein the molecule is a fusion molecule comprising a DNA binding domain and a transcriptional regulatory domain or functional fragments thereof.
- 59. The method of claim 57, wherein the molecule is an endogenous transcriptional regulatory factor.
- 60. The method of claim 57, wherein the region is at least 9 nucleotides in length.
- 61. The method of claim 57, wherein the modulation of the heparanase gene comprises repression of heparanase gene expression.
- 62. The method of claim 61, wherein the transcriptional regulatory domain comprises a repression domain.
- 63. The method of claim 62, wherein the repression domain is selected from the group consisting of (a) KRAB; (b) MBD2B; (c) v-erbA and (d) functional fragments of (a), (b) or (c).
- 64. The method of claim 57, wherein the modulation of the heparanase gene comprises activation of heparanase gene expression.
- 65. The method of claim 64, wherein the transcriptional regulatory domain comprises an activation domain.
- 66. The method of claim 65, wherein the activation domain is selected from the group consisting of (a) VP16; (b) p65; and (c) functional fragments of (a) or (b).
- 67. The method of claim 57, wherein the heparanase gene is in an animal cell.
- 68. The method of claim 67, wherein the cell is a human cell.
- 69. A recombinant expression construct effective in directing the transcription of a selected coding sequence, said expression construct comprising:
(b) a coding sequence; and (b) control elements that are operably linked to said coding sequence, wherein said control elements comprise a polynucleotide derived from a polynucleotide according to claim 41 or a functional fragment thereof, and wherein said coding sequence can be transcribed and translated in a host cell.
- 70. A host cell transformed with the recombinant expression construct of claim 69.
- 71. A method of modulating expression of a target coding sequence in a host cell comprising the step of contacting the host cell with an expression construct according to claim 69, wherein the expression construct comprises the target coding sequence.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH
[0001] Certain of the research described in this application was made with financial support from the United States government, in the form of grant No: 1R43CA86553-01, from the National Cancer Institute. Accordingly, the U.S. government may have certain rights to the claimed subject matter.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/US01/44798 |
11/30/2001 |
WO |
|